Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
Titel:
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
Auteur:
Amadori, Dino Aglietta, Massimo Alessi, Barbara Gianni, Lorenzo Ibrahim, Toni Farina, Gabriella Gaion, Fernando Bertoldo, Francesco Santini, Daniele Rondena, Roberta Bogani, Paola Ripamonti, Carla I